Abilify Orodispersable Tablets 10 mg, 15 mg and 30 mg
- Name:
Abilify Orodispersable Tablets 10 mg, 15 mg and 30 mg
- Company:
Otsuka Pharmaceutical UK Ltd.
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 05/05/20
(Click to Download)XPIL
1. What ABILIFY is and what it is used for
1. What ABILIFY is and what it is used for
2. What you need to know before you take ABILIFY
2. What you need to know before you take ABILIFY
3. How to take ABILIFY
3. How to take ABILIFY
4. Possible side effects
4. Possible side effects
5. How to store ABILIFY
5. How to store ABILIFY
6. Contents of the pack and other information
6. Contents of the pack and other information
Click on this link to Download PDF directly
Otsuka Pharmaceutical UK Ltd.
Company Products
| Medicine Name | Active Ingredients |
|---|---|
| Medicine Name ABILIFY 1 mg/ml oral solution | Active Ingredients aripiprazole |
| Medicine Name ABILIFY 5 mg, 10 mg, 15 mg and 30 mg tablets | Active Ingredients aripiprazole |
| Medicine Name ABILIFY 7.5 mg/ml solution for injection | Active Ingredients aripiprazole |
| Medicine Name Abilify Orodispersable Tablets 10 mg, 15 mg and 30 mg | Active Ingredients aripiprazole |
| Medicine Name Jinarc 15mg, 30mg, 15mg + 45mg, 30mg + 60mg, 30mg + 90mg tablets | Active Ingredients tolvaptan |
| Medicine Name Samsca 7.5 mg, 15mg and 30mg Tablets | Active Ingredients tolvaptan |
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 5 May 2020 PIL
Reasons for updating
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
Section 4 Possible side effects:
- Uncommon side effects (may affect up to 1 in 100 people): the wording ‘eye sensitivity to light’ has been added
- The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known: the wording ‘sensitivity to light’ has been replaced by ‘skin sensitivity to light’
Updated on 5 May 2020 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.8 Undesirable effects: Eye disorders- Uncommon section
‘Photophobia’ has been added
Updated on 21 October 2019 PIL
Reasons for updating
- Change to section 2 - excipient warnings
Free text change information supplied by the pharmaceutical company
Section 2: addition of statement on Abilify containing aspartame and sodium.
Updated on 21 October 2019 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.4: admendments to the statement of aspartame
addition of statement of sodium containment
Section 4.6: added 'metabolites' to section on breastfeeding
Section 4.8: reclassification of a number of adverse events under 'Investigations'. Editorial changes.
Updated on 13 May 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 9 May 2019 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SmPC has been updated as follows:
Update to Section 4.4 Special warnings and precautions for use:
Falls
Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section 4.2).
Update to Section 4.8 Undesirable effects:
Oculogyric crisis is listed under Not known
Updated on 11 December 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 11 December 2018 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Initial upload of SPC